Replies to post #165920 on Biotech Values

[DewDiligence]

ENTA starts phase-1 trial of antibiotic prodrug, EDP-788:

http://finance.yahoo.com/news/enanta-pharmaceuticals-initiates-phase-1-123000900.html

EDP-788 is being studied in a randomized double-blind, placebo-controlled clinical study to evaluate the safety and pharmacokinetics of a single oral dose of EDP-788 in up to 64 healthy volunteers.

… Enanta has created a new class of antibiotics called Bicyclolides. EDP-788, Enanta’s lead antibiotic candidate, is a Bicyclolide developed by Enanta that has demonstrated a broad spectrum of activity against many bacterial organisms, including MRSA. This study, as well as all preclinical and early clinical development of EDP-788, is funded under Enanta’s contract with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

…EDP-788…is being developed for use as an intravenous drug in the hospital setting and for oral dosing in a home setting.

In my ENTA valuation model (#msg-94993406), I ascribed $25M of value to this program.